Clinical trial
A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.
NCT01987284 is registered in ClinicalTrials.gov with Serodus AS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.
- Lead sponsor
- Serodus AS
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2013
- Completion date
- September 30, 2014
- Enrollment
- 17 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.